Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BIRCH: Atezolizumab in PD-L1+ NSCLC
NCT02031458Phase 2Completed
- Sponsor
- Roche
- Start
- Jan 2014
- Primary completion
- May 2015
- Modality
- Monoclonal Antibodies
- Countries
- 19
01
Overview
Phase 2, open-label, single-arm trial of atezolizumab in non-small cell lung cancer (NSCLC), sponsored by Roche. Primary endpoint: Objective Response Rate (IRF) up to 16 months. Started Jan 2014; status: completed.
02
Drugs
atezolizumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT02031458.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02031458.